SUMMARY During each of the four-year periods 1971-1975 and 1975-1979, the annual incidence of hepatitis B infection has been assessed in 56 patients with haemophilia A by measuring plasma HBsAg, anti-HBs and anti-HBc levels. Infection rates of 7% and 9-5% per annum respectively were observed for each four-year period despite the screening of individual blood donations for HBsAg by techniques up to the sensitivity of reversed passive haemagglutination. The highest incidence of seroconversion was amongst severe haemophiliacs many of whom had received treatment predominantly with cryoprecipitate. Of the 16 patients in whom serological evidence of hepatitis B infection was obtained only one had an accompanying clinical episode of hepatitis. We conclude that haemophiliacs are still at high risk of infection by hepatitis B virus despite the screening of individual blood donors for HBsAg.
Despite the development of techniques for screening individual blood donations for evidence of hepatitis B infectivity it is clear that haemophiliacs are still at risk of developing hepatitis. Whilst some episodes of hepatitis may be related to non A non B viruses, others are clearly related to hepatitis B virus (HBV) and these may be asymptomatic particularly in patients with severe haemophilia who receive large quantities of transfused blood products.`4 During the period of this study from 1971 to 1979 two changes have taken place which might influence the rate of hepatitis B infection in haemophiliacs. The at an annual rate of approximately 8% and presumably patients with evidence of immunity were also continuing to have this boosted. As might be expected the rate of conversion is highest amongst young severe haemophiliacs and it is interesting to note that this was despite the predominant use of cryoprecipitate which might be considered to carry a lower risk of transmitting viral infection compared to factor VIII concentrates which are prepared from large plasma pools derived from many hundreds or thousands of donors.6 It is interesting that despite the evidence presented here that over half the patients have evidence of previous hepatitis B infection and frequently abnormal liver function tests"3 none has symptoms referable to chronic liver disease. For the time being HBV will continue to infect haemophiliacs but it is hoped that the risk may decline in the foreseeable future. Firstly since January 1980 all blood donations in Scotland are being screened for HBsAg by radioimmunoassay. Secondly it is possible that hepatitis-free clotting factor concentrates may become available'4 and thirdly active immunisation against hepatitis B may be introduced.'" Mitigating against a future reduction in infection is the fact that the plasma pool size for manufacture of factor VIII is increasing. It is therefore important that studies such as this should continue and we hope to report a further follow-up in due course to include patients who currently do not demonstrate evidence of HBV infection and newly diagnosed haemophiliacs.
Addendum
Since this manuscript was prepared a paper, Hepatitis and haemophilia therapy in Australia by Dr KA Rickard and colleagues (Lancet 1982;ii:146) has appeared. The incidence of hepatitis B infection in Australian haemophiliacs treated predominantly with cryoprecipitate was assessed and found to be identical to the incidence we observed in our Scottish patients. We have gratefully appreciated the assistance of Dr SH Davies who initiated the project. We wish to thank the staff of the Scottish National Blood Transfusion Service for their help.
